Moreover, the European Medicines Agency’s decision to revoke intranasal calcitonin-containing product’s approval for osteoporosis treatment, because of the associated long-term cancer risk, underscores the need for caution.52,53 Nevertheless, calcitonin remains approved for preventing acute bone loss in cases of sudden immobilization, like recent osteoporotic fractures, although its limited availability also restrains its use in this setting. The gene discussed is CALCA; the disease is cancer.